
BioMarin reports a serious adverse event for its phase I/II gene therapy trial for haemophilia A
February 4, 2022 – BioMarin’s gene therapy (valoctocogene roxaparvovec) for haemophilia A is currently in development and not yet licensed by regulators. BioMarin has completed dosing 134 patients in its phase 3 clinical study...